Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London
Globe Newswire•10/11/2026•08:00 ET
0
Key Highlights
- ➤Verrica CEO Jayson Rieger will present at Jefferies Global Healthcare Conference November 19, 2026.
- ➤YCANTH is FDA-approved for molluscum contagiosum in adults and children aged two and older.
- ➤YCANTH is being developed for common warts, dermatology’s largest remaining unmet need.
- ➤Verrica licensed VP-315 worldwide from Lytix Biopharma for non-melanoma skin cancers.
WEST CHESTER, Pa., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Jefferies Global Healthcare Conference in London.
Jefferies Global Healthcare Conference in London Event details: Date: Thursday, November 19, 2026 Time: 1:30pm GMT Location: London, UK
Get started
Create a free account to read the full story.